Abstract: A novel tumor suppressor protein, merlin, is described, including DNA sequences encoding merlin, and recombinant vectors and hosts capable of expressing merlin. Method for the diagnosis and treatment of merlin-associated tumors, and for the diagnosis and treatment of the disease neurofibromatosis 2 (NF2) are also provided.

Abstract: A novel gene, huntingtin, is described, encoding huntingtin protein, recombinant vectors and hosts capable of expressing huntingtin. Methods for the diagnosis and treatment of Huntington's disease are also provided.

Abstract: A novel gene, huntingtin, is described, encoding huntingtin protein, recombinant vectors and hosts capable of expressing huntingtin. Methods for the diagnosis and treatment of Huntington's disease are also provided.

Abstract: The present invention relates, in general, to a novel transport protein, IT10C3. In particular, the present invention relates to nucleic acid molecules coding for IT10C3; IT10C3 polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antisense IT10C3 nucleic acid constructs; antibodies having binding affinity to an IT10C3 polypeptide; hybridomas containing the antibodies; nucleic acid probes for the detection of IT10C3 nucleic acid; a method of detecting IT10C3 nucleic acid or polypeptide in a sample; and kits containing nucleic acid probes or antibodies.

Abstract: The familial dysautonomia gene is identified as located on the long arm of human chromosome 9. As a result of this localization, the presence of the familial dysautonomia gene in a subject of a family with an affected individual is detected by analyzing human chromosome 9 of the subject for a DNA sequence containing the familial dysautonomia gene on the long arm of human chromosome 9 located between D9S59 and D9S127.

Abstract: This invention relates to a DNA segment which encodes at least one member of the family of mammalian G protein-coupled receptor kinases, which maps to the Huntington's disease region within the terminal cytogenic subband of the short arm of chromosome 4, 4p16.3, between DNA marker D4S10 and the telomere region. Further, this invention provides the substantially purified expression product of a gene from the Huntington's disease region of the chromosome, as well as related diagnostic and therapeutic uses.

Abstract: A method for detecting the presence of the gene for Huntington's disease in a subject which comprises analyzing the human chromosome 4 of the subject for a DNA polymorphism, preferably a restriction fragment length polymorphism (RFLP), linked to Huntington's Disease.

Abstract: A process of isolating and identifying cloned DNA segments from defined regions of a chromosome by preparing a series of cell hybrids from a first species and a second species, which hybrids contain a chromosome or deletion mutant of a chromosome as the oThe Government has rights in this invention pursuant to Contract Number CA-5-14051 awarded by the Department of Health and Human Services, Contract Number PCM 77-17747 awarded by the National Science Foundation, and Contract Number 1-713 awarded by the National Foundation-March of Dimes.